Patents by Inventor Hong-An Truong
Hong-An Truong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230382992Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: February 27, 2023Publication date: November 30, 2023Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20230310423Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.Type: ApplicationFiled: June 1, 2023Publication date: October 5, 2023Inventors: Anthony B. PINKERTON, Stephen Todd MEYER, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON
-
Patent number: 11707462Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.Type: GrantFiled: August 29, 2022Date of Patent: July 25, 2023Assignee: BOUNDLESS BIO, INC.Inventors: Anthony B. Pinkerton, Stephen Todd Meyer, Jacques Mauger, Yen Pham Hong Truong, Rachelle Janette Elsdon
-
Publication number: 20230174647Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.Type: ApplicationFiled: June 21, 2022Publication date: June 8, 2023Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
-
Patent number: 11591392Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: GrantFiled: November 27, 2019Date of Patent: February 28, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
-
Publication number: 20230026313Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.Type: ApplicationFiled: August 29, 2022Publication date: January 26, 2023Inventors: Anthony B. PINKERTON, Stephen Todd MEYER, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON
-
Patent number: 11401328Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.Type: GrantFiled: July 9, 2019Date of Patent: August 2, 2022Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
-
Publication number: 20220089720Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.Type: ApplicationFiled: January 11, 2019Publication date: March 24, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20210363242Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.Type: ApplicationFiled: January 15, 2019Publication date: November 25, 2021Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING
-
Publication number: 20210363152Abstract: The disclosure provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt, solvate or salt of the solvate thereof, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 10, 2019Publication date: November 25, 2021Inventors: Jill Melissa Baccei, Yalda Bravo, Austin Chih-Yu Chen, Ryan Christopher Clark, Brian Andrew Stearns, Yen Pham Hong Truong
-
Publication number: 20200190186Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: November 27, 2019Publication date: June 18, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20200079848Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.Type: ApplicationFiled: July 9, 2019Publication date: March 12, 2020Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
-
Patent number: 10533052Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: GrantFiled: June 25, 2018Date of Patent: January 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
-
Patent number: 10399582Abstract: An electronic horn for a train includes a microcontroller and a horn configured to provide an audible output sound, the microcontroller configured to provide one or more signals to the horn indicative of a desired audible output sound from the horn. The microcontroller is configured to vary an intensity of the audible output sound from the horn as a function of a speed of the vehicle. The microcontroller is also configured to vary an intensity of the audible output sound from the horn as a function of a period of time within a calendar. Also, the horn includes a horn body and a compression driver, the horn body being mechanically connected with the compression driver. A feedback loop circuit includes the microcontroller and the compression driver, the feedback loop circuit being configured to control an intensity of the audible output sound from the horn.Type: GrantFiled: October 31, 2016Date of Patent: September 3, 2019Assignee: MICRO PRECISION, LLCInventors: Loi Hong Truong, Hui Li
-
Publication number: 20190248893Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: July 13, 2017Publication date: August 15, 2019Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Y. HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Patent number: 10119117Abstract: In one embodiment, the present application discloses a cell culture medium for culturing cell lines suitable for producing a therapeutic protein, comprising an amino acid selected from a group consisting of L-arginine, L-asparagine, L-proline, L leucine and L hydroxyproline and a mixture thereof; a vitamin selected from a group consisting of ascorbic acid Mg2+ salt, biotin, pyridoxine HCL, folic acid, riboflavin and D-calcium pantothenate, and a mixture thereof; an element selected from a group consisting of ammonium meta vanadate, sodium meta vanadate, germanium dioxide, barium acetate, aluminum chloride, rubidium chloride, cadmium chloride, ammonium molybedate, stannous chloride, cobalt chloride, chromium sulfate, silver nitrate, sodium metasilicate, zinc sulfate, manganese sulfate H2O, manganous chloride, ferric nitrate 9H2O, ferrous sulfate 7H2O, ferric ammonium citrate, magnesium chloride anhydrous, and magnesium sulfate anhydrous, and a mixture thereof; a nucleoside selected from a group consisting of uType: GrantFiled: January 11, 2017Date of Patent: November 6, 2018Assignee: NANOGEN PHARMACEUTICAL BIOTECHNOLOGY CO., LTDInventors: Nhan Ho, Praveen Gupta, Si Minh Do, Phuong Thi Bich Ho, Ngoc-Thuy Bui, Huy Quang Nguyen, Trang Thi Thuy Nguyen, Ha Thi Hong Truong, Tuan Anh Le
-
Publication number: 20180118240Abstract: An electronic horn for a train includes a microcontroller and a horn configured to provide an audible output sound, the microcontroller configured to provide one or more signals to the horn indicative of a desired audible output sound from the horn. The microcontroller is configured to vary an intensity of the audible output sound from the horn as a function of a speed of the vehicle. The microcontroller is also configured to vary an intensity of the audible output sound from the horn as a function of a period of time within a calendar. Also, the horn includes a horn body and a compression driver, the horn body being mechanically connected with the compression driver. A feedback loop circuit includes the microcontroller and the compression driver, the feedback loop circuit being configured to control an intensity of the audible output sound from the horn.Type: ApplicationFiled: October 31, 2016Publication date: May 3, 2018Inventors: Loi Hong Truong, Hui Li
-
Publication number: 20170218328Abstract: In one embodiment, the present application discloses a cell culture medium for culturing cell lines suitable for producing a therapeutic protein, comprising an amino acid selected from a group consisting of L-arginine, L-asparagine, L-proline, L leucine and L hydroxyproline and a mixture thereof; a vitamin selected from a group consisting of ascorbic acid Mg2+ salt, biotin, pyridoxine HCL, folic acid, riboflavin and D-calcium pantothenate, and a mixture thereof; an element selected from a group consisting of ammonium meta vanadate, sodium meta vanadate, germanium dioxide, barium acetate, aluminum chloride, rubidium chloride, cadmium chloride, ammonium molybedate, stannous chloride, cobalt chloride, chromium sulfate, silver nitrate, sodium metasilicate, zinc sulfate, manganese sulfate H2O, manganous chloride, ferric nitrate 9H2O, ferrous sulfate 7H2O, ferric ammonium citrate, magnesium chloride anhydrous, and magnesium sulfate anhydrous, and a mixture thereof; a nucleoside selected from a group consisting of uType: ApplicationFiled: January 11, 2017Publication date: August 3, 2017Applicant: Nanogen Pharmaceutical Biotechnology Co., LtdInventors: Nhan Ho, Praveen Gupta, Si Minh Do, Phuong Thi Bich Ho, Ngoc-Thuy Bui, Huy Quang Nguyen, Trang Thi Thuy Nguyen, Ha Thi Hong Truong, Tuan Anh Le
-
Publication number: 20060262721Abstract: A sensor network has a plurality of wireless sensors which transmit to an intermediate receiving device which relays data to a central server. A method is provided for receiving data packets at the intermediate receiving device from a plurality of the transmitting devices. Data packets are sensed on a communication medium at the receiving device and the total traffic intensity of data packets from the transmitting devices is estimated. A detection threshold for data packets is provided and adapted as a function of the total intensity. The receiving device receives data packets with a signal strength above the current detection threshold.Type: ApplicationFiled: April 26, 2006Publication date: November 23, 2006Applicant: International Business Machines CorporationInventors: Bozidar Radunovic, Hong Truong
-
Publication number: 20050286410Abstract: The present invention discloses an apparatus and method for adapting a transmission parameter in a transmitting node of a data communication system to the current link quality of a data communication channel. The adapted transmission parameter is selected by the transmitting node from a set of transmission parameters in dependence on a number of successful transmissions. The number of successful transmissions is compared in the transmitting node against one of a first threshold value corresponding to a first state of the transmitting node and a second threshold value corresponding to a second state of the transmitting node.Type: ApplicationFiled: June 17, 2003Publication date: December 29, 2005Inventors: Hong Truong, Andre Barreto, Jena Jelitto